Clinical trial • Musculoskeletal
Alendronic acid (Alendronate) for Osteoporosis
Clinical trial of Alendronic acid (Alendronate) for Osteoporosis.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Osteoporosis
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 09-06-2024
- First CTIS Authorization Date
- 22-07-2024
Trial design
Randomised, alendronate continuation versus discontinuation (comparator details: dose and schedule not specified in record).-controlled trial across 8 sites in Denmark.
- Randomised
- Yes
- Comparator
- Alendronate continuation versus discontinuation (comparator details: dose and schedule not specified in record).
- Target Sample Size
- 1400
- Trial Duration For Participant
- 1095
Eligibility
Recruits 1400 No vulnerable populations selected (isVulnerablePopulationSelected=false). Consent obtained from adult participants; subject information and informed consent forms for adults are provided. No assent or parental consent for minors is mentioned..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected=false). Consent obtained from adult participants; subject information and informed consent forms for adults are provided. No assent or parental consent for minors is mentioned.
Inclusion criteria
- {"criterion_text":"-Female, Postmenopausal, Current treatment with Alendronate, Alendronate treatment >3 år AND no previous major osteoporotic fracture OR Alendronate treatment >5 år AND latest major osteporotic fracture > 3 years ago, ** Major osteoprotic fracture is defined as low energy fractures in hip, proximal humerus, distal radius, or vertebral fracture"}
Exclusion criteria
- {"criterion_text":"-T-score < - 3,5 in hip (total hip or femoral neck) or lumbar spine, Treatment with systemic glucocorticoids for more than two weeks, ongoing or within 12 months, Uncontrolled inflammatory disease, Active malignancy, eGFR < 40 mL/min, Atypical femur fracture (ever), OsteoNecrosis of the Jaw (active), Unable to give inform consent"}
Endpoints
Primary endpoints
- {"endpoint_text":"-Incidence of fragility fractures during the study periode","definition_or_measurement_approach":"Not further defined in the record; stated as incidence of fragility fractures during the study period."}
Secondary endpoints
- {"endpoint_text":"-Changes in BMD spine and hip from inclusion to study end (3 years), Changes in Bone Turnover Markers over the study period (CTX and P1NP),Proportion of patients meeting restart criteria ,Adverse events.","definition_or_measurement_approach":"Changes in BMD spine and hip measured from inclusion to study end (3 years); Bone turnover markers (CTX and P1NP) measured over study period; proportion meeting restart criteria (criteria not specified here); adverse events recorded (details not specified here)."}
Recruitment
- Planned Sample Size
- 1400
- Recruitment Window Months
- 60
- Consent Approach
- Informed consent obtained from participants. Multiple subject information and informed consent forms for adults are provided (documents listed in CTIS). Participants are adults (postmenopausal females); no assent or parental consent arrangements are mentioned.
Geography
- Total Number Of Sites
- 8
- Total Number Of Participants
- 1400
Denmark
- Earliest CTIS Part Ii Submission Date
- 15-07-2024
- Latest Decision Or Authorization Date
- 08-08-2025
- Processing Time Days
- 389
- Number Of Sites
- 8
- Number Of Participants
- 1400
Sites
- Site Name
- Copenhagen University Hospital
- Department Name
- Endocrinology
- Principal Investigator Name
- Jakob Præst Holm
- Principal Investigator Email
- jakob.praest.holm.01@regionh.dk
- Contact Person Name
- Jakob Præst Holm
- Contact Person Email
- jakob.praest.holm.01@regionh.dk
- Site Name
- Nordsjaellands Hospital
- Department Name
- Endocrinology
- Principal Investigator Name
- Louise Tjelum
- Principal Investigator Email
- louise.tjelum@regionh.dk
- Contact Person Name
- Louise Tjelum
- Contact Person Email
- louise.tjelum@regionh.dk
- Site Name
- Esbjerg Og Grindsted Sygehus
- Department Name
- Endocrinology
- Principal Investigator Name
- Jeppe Gram
- Principal Investigator Email
- svs-forskning@rsyd.dk
- Contact Person Name
- Jeppe Gram
- Contact Person Email
- svs-forskning@rsyd.dk
- Site Name
- Odense University Hospital
- Department Name
- Endocrinology
- Principal Investigator Name
- Pernille Hermann
- Principal Investigator Email
- pernille.hermann@rsyd.dk
- Contact Person Name
- Pernille Hermann
- Contact Person Email
- pernille.hermann@rsyd.dk
- Site Name
- Bispebjerg Hospital
- Department Name
- endocrinology
- Principal Investigator Name
- pia eiken
- Principal Investigator Email
- pia.eiken.01@regionh.dk
- Contact Person Name
- pia eiken
- Contact Person Email
- pia.eiken.01@regionh.dk
- Site Name
- Region Syddanmark
- Department Name
- Internal Medicine
- Principal Investigator Name
- Frans Hjelm Brandt Kristensen
- Principal Investigator Email
- FBK@rsyd.dk
- Contact Person Name
- Frans Hjelm Brandt Kristensen
- Contact Person Email
- FBK@rsyd.dk
- Site Name
- Aalborg University Hospital
- Department Name
- endocrinology
- Principal Investigator Name
- peter vestergaard
- Principal Investigator Email
- p.vestergaard@rn.dk
- Contact Person Name
- peter vestergaard
- Contact Person Email
- p.vestergaard@rn.dk
- Site Name
- Hvidovre Hospital
- Department Name
- Endocrinology
- Principal Investigator Name
- Jens-Erik Bech Jensen
- Principal Investigator Email
- jens-erik.beck-jensen@regionh.dk
- Contact Person Name
- Jens-Erik Bech Jensen
- Contact Person Email
- jens-erik.beck-jensen@regionh.dk
Sponsor
Primary sponsor
- Full Name
- Odense University Hospital
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Odense University Hospital","duties_or_roles":"sponsorDuties codes: 1, 8","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- ALENDRONIC ACID
- Active Substance
- Alendronic acid (Alendronate)
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Maximum Dose
- 10 mg (maxDailyDoseAmount = 10 mg)
- Investigational Product Name
- TETRACYCLINE
- Active Substance
- Tetracycline hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- oral
- Maximum Dose
- 1000 mg (maxDailyDoseAmount = 1000 mg)
Related trials
Other published trials that may interest you.